Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation

Yano, Ikuko; Masuda, Satohiro; Egawa, Hiroto; Sugimoto, Mitsuhiro; Fukudo, Masahide; Yoshida, Yasuhiko; Hashi, Sachiyo; Yoshizawa, Atsushi; Ogura, Yasuhiro; Ogawa, Kohei; Mori, Akira; Kaido, Toshimi; Üemoto, Shinji; Inui, Ken Ichi

doi:10.1007/s00228-011-1129-x

Cited by 17 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, we report here that blood levels of CsA and trough levels of CN-a are not correlated. This observation is in agreement with previous findings in hematopoietic stem-cell transplant-, in liver transplant- and in kidney transplant-patients [20], [21], [24], [31], [32]. However, the absence of correlation between CN-a levels and CsA whole blood concentrations does not mean that the latter is not a predictor of patient outcome.…”

Section: Discussionsupporting

confidence: 93%

Expression of Calcineurin Activity after Lung Transplantation: A 2-Year Follow-Up

et al. 2013

View full text Add to dashboard Cite

The objective of this pharmacodynamic study was to longitudinally assess the activity of calcineurin during the first 2 years after lung transplantation. From March 2004 to October 2008, 107 patients were prospectively enrolled and their follow-up was performed until 2009. Calcineurin activity was measured in peripheral blood mononuclear cells. We report that calcineurin activity was linked to both acute and chronic rejection. An optimal activity for calcineurin with two thresholds was defined, and we found that the risk of rejection was higher when the enzyme activity was above the upper threshold of 102 pmol/mg/min or below the lower threshold of 12 pmol/mg/min. In addition, we report that the occurrence of malignancies and viral infections was significantly higher in patients displaying very low levels of calcineurin activity. Taken together, these findings suggest that the measurement of calcineurin activity may provide useful information for the management of the prevention therapy of patients receiving lung transplantation.

show abstract

Section: Discussionsupporting

confidence: 93%

Expression of Calcineurin Activity after Lung Transplantation: A 2-Year Follow-Up

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Different investigations carried out in liver transplant recipients have already investigated the relationship between TAC whole blood concentrations and calcineurin activity in PBMC [16,17,[31][32][33] or between concentrations of TAC in whole blood and PBMC [10,14,34]. To our best knowledge, the present study is the first to study both the pharmacokinetics of TAC in whole blood and leukocytes as well as the TAC-induced effect on calcineurin activity in leukocytes.…”

Section: Discussionmentioning

confidence: 85%

Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells

Lemaître

Blanchet

Latournerie

et al. 2015

Clinical Biochemistry

View full text Add to dashboard Cite

Drug monitoring of TAC intracellular concentrations and determination of the calcineurin activity are among future potential biomarkers of acute rejection in transplant recipients. A better knowledge of the relationship between TAC whole blood and intracellular concentrations and calcineurin activity appears necessary before planning clinical trials to evaluate their potential interest as predictive biomarkers.

show abstract

“…The measurement of CN phosphatase activity in peripheral blood mononuclear cells (PBMCs) is a pharmacodynamic biomarker used to evaluate the immunosuppressive effect of CN inhibitors 11 . The CN activity at the trough time point was suggested to be a surrogate 8 indicator of overall CN activity throughout the dosing intervals after administration of the TD tacrolimus formulation in LDLT patients 12 . In this study, we investigated the pharmacokinetics and pharmacodynamics of tacrolimus using the OD formulation with simultaneous measurements of blood tacrolimus concentrations and CN activity in the early stage after LDLT and compared the data with previously reported data of the TD formulation 12 .…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation

Iwasaki

Yano

Hashi

et al. 2018

Therapeutic Drug Monitoring

Self Cite

View full text Add to dashboard Cite

The C0 monitoring of the OD formulation may not be optimal in patients at the early stage after LDLT because the C0 was not correlated with the AUC0-24. If clinicians target the same C0 using the OD and TD formulations, the exposure of tacrolimus can be higher in the OD formulation, and excessive immunosuppression should be noted. Particular attention should be paid to the patients in the early stage after LDLT in the use of the OD oral formulation of tacrolimus.

show abstract

Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation

Cited by 17 publications

References 22 publications

Expression of Calcineurin Activity after Lung Transplantation: A 2-Year Follow-Up

Expression of Calcineurin Activity after Lung Transplantation: A 2-Year Follow-Up

Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells

Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation

Contact Info

Product

Resources

About